GlassScriptPhysician profile
Jenny Farley Mason
NPI 1710549928
$3,166.09
in general payments reported to CMS, 2019-2025
27 companies · $79.54 in 2025
The $79.54 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,161 · 2022: $1,433 · 2023: $443 · 2024: $50.09 · 2025: $79.54.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $572.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $572.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $480.55 | 2021-2023 | Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $365.43 | 2021-2023 | Jardiance, Synjardy |
| Bayer Healthcare Pharmaceuticals INC. | $273.94 | 2021-2023 | |
| Dexcom, INC. | $268.79 | 2021-2023 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $206.39 | 2021-2022 | |
| Antares Pharma, INC. | $204.82 | 2021-2023 | Xyosted, Tlando, Nocdurna |
| Xeris Pharmaceuticals, INC. | $204.28 | 2021-2023 | Gvoke Hypopen, Recorlev |
| Lilly USA, LLC | $154.83 | 2022 | |
| Amgen INC. | $105.24 | 2021-2022 | |
| Corcept Therapeutics | $101.02 | 2021-2025 | Korlym |
| Radius Health, INC. | $97.96 | 2021-2023 | Tymlos |
| Sanofi-Aventis U.S. LLC | $91.65 | 2022-2023 | |
| Tandem Diabetes Care, INC. | $79.25 | 2021-2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Novartis Pharmaceuticals Corporation | $77.30 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $69.25 | 2021-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grt US Holding, INC. | $50.32 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $48.73 | 2022-2023 | Strensiq |
| Amryt Pharma Holdings LTD | $46.33 | 2022 | |
| Mannkind Corporation | $43.14 | 2021 | |
| Medtronic, INC. | $39.75 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $38.51 | 2022 | |
| Abbvie INC. | $33.12 | 2022-2023 | |
| Esperion Therapeutics, INC. | $20.33 | 2021 | |
| Idorsia Pharmaceuticals US INC | $19.07 | 2023 | Quviviq |
| Horizon Therapeutics Plc | $16.57 | 2021 | |
| Arbor Pharmaceuticals, INC. | $15.12 | 2021 | |
| Madrigal Pharmaceuticals | $14.40 | 2025 | Rezdiffra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jenny Mason listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.